- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: Protein subfamily.
Displaying page 1 of 1.
EudraCT Number: 2008-007789-51 | Sponsor Protocol Number: B1971005(6108A1-2001-WW) | Start Date*: 2009-03-23 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µ... | |||||||||||||
Medical condition: The test is a vaccine. The subjects are healthy adolescents. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) ES (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004313-13 | Sponsor Protocol Number: C3511001 | Start Date*: 2020-08-27 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY PARTICIPANTS ≥10 TO <26 YEARS OF AGE | |||||||||||||
Medical condition: Invasive Meningococcal Disease (IMD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) CZ (Completed) HU (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000933-21 | Sponsor Protocol Number: B1971017 | Start Date*: 2015-07-06 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, CONTROLLED, OBSERVER-BLINDED STUDY TO DESCRIBE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF NEISSERIA MENINGITIDIS SEROGROUP B BIVALENT RECOMBINANT LIPOPROTEIN 2086 VACCIN... | |||||||||||||
Medical condition: Invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023873-20 | Sponsor Protocol Number: B1971009(6108A1-3001) | Start Date*: 2011-11-08 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MENINGOCOCCAL SEROGROUP B BIVALENT RLP2086 VACCINE IN H... | |||||||||||||
Medical condition: BACTERIAL MENINGITIS. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) FI (Completed) CZ (Completed) GB (Completed) ES (Completed) PL (Completed) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004400-38 | Sponsor Protocol Number: B1971035 | Start Date*: 2015-07-08 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A Phase 2, Randomized, Controlled, Observer-blinded Study, Conducted to Describe the Immunogenicity, Safety, and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotei... | |||||||||||||
Medical condition: Invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002588-24 | Sponsor Protocol Number: B1971060 | Start Date*: 2021-06-16 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 4, OPEN-LABEL, SINGLE-ARM TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF TRUMENBA® WHEN ADMINISTERED TO IMMUNOCOMPROMISED PARTICIPANTS ≥10 YEARS OF AGE | |||||||||||||
Medical condition: prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000948-60 | Sponsor Protocol Number: C3511002 | Start Date*: 2021-01-19 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2b TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY INFANTS 2 AND 6 MONTHS OF AGE | |||||||||||||
Medical condition: Invasive Meningococcal Disease (IMD) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004461-41 | Sponsor Protocol Number: MET59 | Start Date*: 2020-02-14 | |||||||||||
Sponsor Name:Sanofi Pasteur Inc | |||||||||||||
Full Title: Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults | |||||||||||||
Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y and W) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004421-17 | Sponsor Protocol Number: B1971057 | Start Date*: 2020-02-17 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF BIVALENT rLP2086 WHEN ADMINISTERED AS A 2-DOSE REGIMEN AND A FIRST-IN-HUMA... | |||||||||||||
Medical condition: Active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W and Y in individuals 10 through 25 years of age. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) FI (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003070-31 | Sponsor Protocol Number: VAN00002 | Start Date*: 2022-01-24 | |||||||||||
Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||
Full Title: Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants | |||||||||||||
Medical condition: Invasive Meningococcal Disease (IMD) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022449-38 | Sponsor Protocol Number: B1971010(6108A1-2008) | Start Date*: 2011-02-21 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-BLIND TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REPEVAX AND BIVALENT rLP2086 VACCINE WHEN ADMINISTERED CONCOMITANTLY IN HEALT... | |||||||||||||
Medical condition: Healthy volunteers (prevention of bacterial meningitis). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014492-46 | Sponsor Protocol Number: B1971016(6108A1-2004) | Start Date*: 2011-05-19 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED, TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BIVALENT rLP2086 VACCINE WHEN ADMINISTERED AS A 3-DOSE REGIMEN IN HEALTH... | |||||||||||||
Medical condition: Pfizer‘s investigational bivalent rLP2086 vaccine is being developed for prevention of invasive meningococcal disease caused by N meningitidis serogroup B. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) PL (Completed) DK (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2023-000924-13 | Sponsor Protocol Number: VAN00010 | Start Date*: 2023-12-21 | |||||||||||
Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||
Full Title: A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity study to assess Pentavalent Meningococcal ABCYW Vaccine formulations in Adults (18 to 25 years of age) and Adolescents (10 to 17 yea... | |||||||||||||
Medical condition: Bacterial infections and mycoses | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004609-42 | Sponsor Protocol Number: OVG2017/08 | Start Date*: 2018-02-21 | ||||||||||||||||
Sponsor Name:Clinical Trials and Research Governance (CTRG), University of Oxford | ||||||||||||||||||
Full Title: Evaluating the effect of immunisation with group B meningococcal vaccines on meningococcal carriage | ||||||||||||||||||
Medical condition: Oropharyngeal meningococcal carriage. Meningococci have the potential to cause invasive meningococcal disease. This study investigates the ability of Meningococcal B vaccines to reduce the carriage... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001200-15 | Sponsor Protocol Number: ALXN1210-DM-310 | Start Date*: 2021-10-05 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis. | |||||||||||||
Medical condition: Dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001229-26 | Sponsor Protocol Number: ALXN2050-MG-201 | Start Date*: 2021-12-21 | |||||||||||
Sponsor Name:ALEXION PHARMACEUTICALS INCORPORATED | |||||||||||||
Full Title: A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis | |||||||||||||
Medical condition: Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001426-22 | Sponsor Protocol Number: ALXN2050-NEPH-201 | Start Date*: 2022-05-30 | ||||||||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunogl... | ||||||||||||||||||
Medical condition: Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001198-22 | Sponsor Protocol Number: ALXN2040-GA-201 | Start Date*: 2021-12-02 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) | |||||||||||||
Medical condition: Geographic Atrophy (AD) secondary to Age-related Macular Degeneration (AMD). | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
